Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.
Hiramatsu N, Kasahara A, Nakanishi F, Toyama T, Tsujii M, Tsuji S, Kanto T, Takehara T, Kato M, Yoshihara H, Naito M, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Meren H, Masuzawa M, Haruna Y, Mita E, Suzuki K, Hayashi N. Hiramatsu N, et al. Among authors: suzuki k. Hepatol Res. 2004 Jul;29(3):142-147. doi: 10.1016/j.hepres.2004.03.008. Hepatol Res. 2004. PMID: 15203077
Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
Hiramatsu N, Oze T, Tsuda N, Kurashige N, Koga K, Toyama T, Yasumaru M, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Haruna Y, Mita E, Suzuki K, Ishibashi K, Hayashi N. Hiramatsu N, et al. Among authors: suzuki k. Hepatol Res. 2006 Jul;35(3):185-9. doi: 10.1016/j.hepres.2006.03.008. Epub 2006 May 4. Hepatol Res. 2006. PMID: 16678478
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T. Oze T, et al. Among authors: suzuki k. J Gastroenterol. 2015 Mar;50(3):313-22. doi: 10.1007/s00535-014-0965-8. Epub 2014 May 8. J Gastroenterol. 2015. PMID: 24806033 Clinical Trial.
Impact of branched-chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study.
Imanaka K, Ohkawa K, Tatsumi T, Katayama K, Inoue A, Imai Y, Oshita M, Iio S, Mita E, Fukui H, Yamada A, Nakanishi F, Inada M, Doi Y, Suzuki K, Kaneko A, Marubashi S, Ito Y, Fukui K, Sakamori R, Yakushijin T, Hiramatsu N, Hayashi N, Takehara T; Osaka Liver Forum. Imanaka K, et al. Among authors: suzuki k. Hepatol Res. 2016 Sep;46(10):1002-10. doi: 10.1111/hepr.12640. Epub 2016 Jan 26. Hepatol Res. 2016. PMID: 26690886
Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines.
Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T, Honke K, Suzuki K, Yoshihara H, Yoshikawa K, Kawano K, Tonetti M, Kasahara A, Hori M, Hayashi N, Taniguchi N. Noda K, et al. Among authors: suzuki k. Cancer Res. 2003 Oct 1;63(19):6282-9. Cancer Res. 2003. PMID: 14559815
[Investigation of simplified international diagnostic criteria for autoimmune hepatitis].
Kaneko A, Kubo M, Yamada R, Tanimura T, Yamaguchi D, Yamamoto M, Tatsumi N, Nakama A, Mita E, Kato M, Hijioka T, Oshita M, Ito T, Imanaka K, Katayama K, Sato M, Yoshihara H, Kiriyama K, Imai Y, Kashihara T, Fukui H, Suzuki K, Miyoshi S, Yamada A, Yakushijin T, Mochizuki K, Hiramatsu N, Takehara T, Hayashi N. Kaneko A, et al. Among authors: suzuki k. Nihon Shokakibyo Gakkai Zasshi. 2010 May;107(5):732-42. Nihon Shokakibyo Gakkai Zasshi. 2010. PMID: 20460847 Japanese.
Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum.
Hirao M, Komori M, Nishida T, Iijima H, Yamaguchi S, Ishihara R, Yasunaga Y, Kobayashi I, Kishida O, Oshita M, Hagiwara H, Ito T, Suzuki K, Hayashi Y, Inoue T, Tsujii M, Yoshihara H, Takehara T. Hirao M, et al. Among authors: suzuki k. Oncol Lett. 2017 Aug;14(2):1628-1636. doi: 10.3892/ol.2017.6290. Epub 2017 Jun 1. Oncol Lett. 2017. PMID: 28789389 Free PMC article.
19,722 results
You have reached the last available page of results. Please see the User Guide for more information.